Sterile Oncology Injectable Market Segments, Opportunity, Growth and Forecast By End-use Industry 2018 - 2028

Increasing Demand of Oncology Injectable

Injectable drug delivery is the mode of introduction of a drug directly into the bloodstream of patient. Drugs are directly injected into bloodstream of patients therefore it needs to be sterile. Sterile injectable drugs are the usually available in liquid form. Sterile injectable drugs are usually permit to transport directly into blood stream sometimes. The manufacturing of sterile injectable drugs is a complex process and recurs high initial investment and operating cost. Major factor to increase demand of global sterile injectable market is increasing number of cancer cases. According to World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were accounted worldwide in 2012. As per WCRFI, till 2035, around 24 million cancer cases are expected to increase. Smalll molecule monoclonal antibodies used for cancer treatment therapy. Cancer therapies are the import engine of growth for sterile oncology injectable market.

Focusing on Technologies, Materials and Robust Manufacturing Process

Quantity of drugs in short supply in the US remains in predominant with some shortage continuing for multiple year. The majority of these drugs are generic sterile injectable products due to supply due to manufacturing. Companies are focusing on increase in supply of sterile oncology injectable. Manufactures are now focusing on superior technology and procurement of higher grade raw materials. Contract manufacturing organization can help to address drug shortage problem in North America and Europe. They adopt new technologies and rapidly transfer in sterile injectable manufacturing processes.

Request Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-6604

Sterile Oncology Injectable Market Assessment by Product Type
sterile oncology injectable market

Growth Due to Rising Investment by Drug Manufacture

Global sterile oncology injectable market is projected witness significant growth over the forecast period due to rising prevalence of cancer globally. Increase in investment by drug manufactures in the development of sterile oncology injectable, short time frame for approval of new drug in cancer treatment are some of the key factor boosting demand for sterile oncology injectable market globally. Rapid FDA approvals of sterile oncology injectable along with shortened approval times for drug development in cancer care is helping manufacturers to accelerate drug supplies. These factors are eventually boosting demand of global sterile oncology injectable market. However stringent rules and regulations in manufacture of sterile oncology injectable and high quality and care required in manufacturing, challenges in storage, packaging and distribution of oncological sterile injectable are likely to hamper the growth of sterile oncology injectable market. Sterile drugs require complex equipment for manufacturing.

Market Expansion Due to Agreement and Partnership

Sterile oncology injectable manufacture are focusing on partnership and geographical expansion in different countries to establish facilities in various regions. For example through the Baxter partnership with Scinopharm 20 injectable cancer drugs will be facilities in Taiwan and Germany. Pfizer expands its oncology portfolio with Hospira acquisition. Hospira has a broad sterile injectable product line which includes acute care and oncology injectable. Baxter also acquire India based injectable firm Claris injectable limited and expand its portfolio in anti-infective, analgesics and critical care and oncology injectable.

Regional Market Outlook

Geographically, global sterile oncology injectable market is segmented into eight key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, China, Japan and Middle East & Africa. North America will continue to dominate the global market as due to the availability of advanced technologies and more number of clinical trial, surge in demand for innovative medical technology in the U.S. According to the National Institute of Cancer in 2016, around 1,685,210 new cancer cases are likely to be diagnosed in the U.S. Europe is expected to hold second largest market share in global sterile oncology injectable market due to growing prevalence of chronic diseases. Competition from low cost pharmaceutical manufacturing countries such as India and China has led to discontinuation of many products in the segment for economies of scale. Asia Pacific is expected to exhibit attractive market share owing to increase in health awareness and demand for advanced medical technology in oncology treatment and increasing infrastructure on low cost pharmaceutical manufacturing.

Competition Outlook

Some of the players identified in the global sterile oncology injectable market are Eli Lilly & Company, Biocon Ltd, Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceuticals Industries Ltd, and Pfizer Inc. Etc. Sterile oncology injectable are used for cancer treatment and therapies. Recent M&A activities have fueled the growth prospect for sterile oncology injectable. Recent deal of US$ 17 Billion between Pfizer & Hospira provides platform for growth for Pfizer’s Global Established Pharmaceutical (GEP) business. Hospira’s generic sterile injectable products, including acute care and oncology injectable have provided boost to Pfizer’s sterile injectable offerings in oncology market. However, preference of large molecules offers a global opportunity to its manufacturers, as these are the common molecules recently used globally for oncology application.

Sterile CMOs


Medium Scale Manufacturers/Providers


Large Scale Manufacturers/Providers

Catalent Pharma Solutions

Baxter

Akorn

Althea

Vetter

Piramal Pharma Solutions (ColdStream Laboratories)

IDT Biologica.



Biocon Ltd

Baxter International Inc.

Hikma Pharmaceuticals PLC

Sandoz International GmbH



Mylan N.V

Teva Pharmaceuticals Industries Ltd

Pfizer Inc.

Eli Lilly & Company

Visit For Table of Contents: https://www.futuremarketinsights.com/toc/rep-gb-6604

Key data points covered in report

The report covers exhaustive analysis on:

Sterile oncology injectable market by molecule type, distribution channel, indication and region
Regional level market analysis of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding China & Japan, China, Japan, Middle East & Africa by molecule type, distribution channel, indication and country segments
Sterile Oncology Injectable Market Dynamics & Opportunity Assessment
Historical Actual Market Size, 2013 - 2017
Sterile Oncology Injectable Market Size & Forecast 2018-2028
Sterile Oncology Injectable Market Current Trends/Issues/Challenges
Competition & Companies involved

About Us – Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

Contact Us:
Future Market Insights
616 Corporate Way,
Suite 2-9018,
Valley Cottage,
New York 10989,
United States
Tel: +1-347-918-3531
Fax: +1-845-579-5705
mail: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com/

This release was published on openPR.